| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 03/28/2002 | WO2002024693A1 A process for producing 3,4-dihydro naphthyridinone analogs |
| 03/28/2002 | WO2002024685A1 Indole derivatives and their use as antifungal and/or antiparasitic agents |
| 03/28/2002 | WO2002024684A1 Quinoline derivatives as antibacterials |
| 03/28/2002 | WO2002024683A1 Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derivatives |
| 03/28/2002 | WO2002024679A1 PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-β) INHIBITING ACTIVITY |
| 03/28/2002 | WO2002024674A1 Benzoic acid derivatives and uses thereof |
| 03/28/2002 | WO2002024651A1 A process for producing 2-amino-4,6-disubstituted nicotinic acid ester analogs |
| 03/28/2002 | WO2002024650A2 Pyridinone and pyridinethione derivatives having hiv inhibiting properties |
| 03/28/2002 | WO2002024647A1 Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient |
| 03/28/2002 | WO2002024636A2 N-acylsulfonamide apoptosis promoters |
| 03/28/2002 | WO2002024307A2 Reducing the content of particular cell types in a biological sample |
| 03/28/2002 | WO2002024225A1 Use of immidazoquinolinamines as adjuvants in dna vaccination |
| 03/28/2002 | WO2002024224A2 Use of replication-deficient poxvirus vector to boost cd4+ t cell immune response to antigen |
| 03/28/2002 | WO2002024223A2 Prevention and treatment of streptococcal and staphylococcal infection |
| 03/28/2002 | WO2002024220A2 Vaccine comprising heat stress proteins from herbaceous plants |
| 03/28/2002 | WO2002024217A1 Use of il-8 protein modulators in the treatment of viral infections |
| 03/28/2002 | WO2002024211A1 Immunomodulatory preparation |
| 03/28/2002 | WO2002024210A2 Halogen compounds for use in medicine |
| 03/28/2002 | WO2002024207A1 Diuretic or sulphonylurea for use in antiviral treatment |
| 03/28/2002 | WO2002024197A1 Fatty acid synthase inhibitors |
| 03/28/2002 | WO2002024180A2 Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia |
| 03/28/2002 | WO2002024145A2 Antiviral substances from plant cuticular and epicuticular material |
| 03/28/2002 | WO2002023990A1 Disinfectant |
| 03/28/2002 | WO2002016554A9 Probiotics products containing lactic acid bacterium |
| 03/28/2002 | WO2002009651A3 Fatty acid synthase inhibitors |
| 03/28/2002 | WO2002002595A9 Amphipathic linear peptides and compositions containing same |
| 03/28/2002 | WO2002000266A3 A method of treating and preventing infectious diseases |
| 03/28/2002 | WO2001098333A3 Modification of hepatitis b core antigen |
| 03/28/2002 | WO2001097751A3 New formulation comprising a betablocker and optionally a cholesterol-lowering agent |
| 03/28/2002 | WO2001094952A3 Methods and compositions for modulating oxidized ldl transport |
| 03/28/2002 | WO2001090106A3 Tryasolyl tropane derivatives as ccr5 modulators |
| 03/28/2002 | WO2001085772A3 Virulence genes, proteins, and their use |
| 03/28/2002 | WO2001085770A3 Sentinel virus ii |
| 03/28/2002 | WO2001085762B1 Cancer diagnosis and assays for screening anti-cancer agents |
| 03/28/2002 | WO2001080822A3 Effervescent granules and methods for their preparation |
| 03/28/2002 | WO2001079249A3 Peptide nucleic acid derivatives with a negative charge, agents and methods for producing them |
| 03/28/2002 | WO2001078774A3 Recombinant intracellular pathogen vaccines and methods for use |
| 03/28/2002 | WO2001076585A3 Use of thiamphenicol for the treatment of chlamydia pneumoniae infections |
| 03/28/2002 | WO2001066107A3 Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases |
| 03/28/2002 | WO2001060344A3 Use of thiamphenicol in the treatment of vancomycin-intermediates and multiresistant staphylococci infections |
| 03/28/2002 | WO2001056553A3 Pharmaceutically active aromatic guanylhydrazones |
| 03/28/2002 | WO2001055357A3 Myeloid colony stimulating factor and uses thereof |
| 03/28/2002 | WO2001055356A3 Human protein kinases and protein kinase-like enzymes |
| 03/28/2002 | WO2001055330A3 Recombinant rhabdoviruses as live-viral vaccines for immunodeficiency viruses |
| 03/28/2002 | WO2001032216A3 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 03/28/2002 | WO2001009183A3 Polymorphisms in the human mdr-1 gene and applications thereof |
| 03/28/2002 | WO2000063241A9 Methods and compositions for modulating an immune response |
| 03/28/2002 | WO2000061611A9 Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences |
| 03/28/2002 | US20020038469 Delayed progression to aids by a missense allele of the ccr2 gene |
| 03/28/2002 | US20020038033 Treating tetrahydrofuran derivativ with an oxophilic electrophilic reagent in a manner that is effective to provide the oxazoline compound |
| 03/28/2002 | US20020038025 For therapy and prophylaxis of hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasite infections, gallstones, tumors and/or hyperproliferative disorders, diabetes |
| 03/28/2002 | US20020037998 For therapy of hepatitis C virus (HCV) infection |
| 03/28/2002 | US20020037933 Sterile pharmaceutical for parenteral administration which comprises the compound 2,6-diisopropylphenol (propofol) with a sterile diluent or carrier; counteracting endotoxin induced deterioration of arterial oxygen tension |
| 03/28/2002 | US20020037927 Halogenated 2-amino-4, 5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/28/2002 | US20020037915 4-(4-(1- phenyl-5-propylpyrazol4-yl)(1,3-thiazol-2-yl))-5-methylthiothiophene-2 -carboxamidine, for example; complement inhibitors; treating tissue damage, inflammation, or autoimmune diseases |
| 03/28/2002 | US20020037900 Hydroxamic acid derivatives |
| 03/28/2002 | US20020037895 Wherein the lactone ring is modified; preventing or treating disorders or diseases mediated by LFA-1 (Leukocyte Function-associated Antigen-1) ICAM-1 (intercellular adhesion molecules) interactions; autoimmune disorders, inflammation |
| 03/28/2002 | US20020037891 Novel benzo[1,8]naphthyridine derivatives, their preparation and pharmaceutical compositions which comprise them |
| 03/28/2002 | US20020037890 Synergistic; treating grampositive and gramnegative bacterial infections, kits |
| 03/28/2002 | US20020037889 Imidazolidin-2-one derivatives; inhibiting bone resorption, vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, arthritis, viral disease, cancer and metastatic tumor growth |
| 03/28/2002 | US20020037878 Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| 03/28/2002 | US20020037874 Anticoagulants |
| 03/28/2002 | US20020037873 Biologically active phosphotriester-type compounds |
| 03/28/2002 | US20020037865 Crystal structure |
| 03/28/2002 | US20020037856 Novel compounds possessing antibacterial, antifungal or antitumor activity |
| 03/28/2002 | US20020037852 Anticarcinogenic agents |
| 03/28/2002 | US20020037841 Blood disorders; drug in aqueous solution |
| 03/28/2002 | US20020037835 Antitumor agents |
| 03/28/2002 | US20020037572 Novel mammalian secreted group III phospholipase A2 |
| 03/28/2002 | US20020037549 ABC transport polynucleotides, polypeptides, and antibodies |
| 03/28/2002 | US20020037524 Nucleotide sequences for use in diagnosis, treatment and prevention of cancer, inflammation, autoimmune disease and infections |
| 03/28/2002 | US20020037523 Nucleotide sequences coding polypeptide for use in the diagnosis, treatment and prevention of nervous system, autoimmune, inflammation, glomerulonephritis and osteoporosis disorders |
| 03/28/2002 | US20020037491 Oral transmucosal delivery |
| 03/28/2002 | US20020037326 Peptides for inhibiting retroviruses |
| 03/28/2002 | US20020037324 Aqueous solubility pharmaceutical formulations |
| 03/28/2002 | US20020037322 Composition comprising a crystallographically stable, amorphous cephalosporin and processes for the preparation thereof |
| 03/28/2002 | US20020037295 Oral or intranasal vaccines using hydrophobic complexes having proteosomes and lipopolysaccharides |
| 03/28/2002 | US20020037293 Chlamydia antigens and corresponding DNA fragments and uses thereof |
| 03/28/2002 | US20020037292 Avian polynucleotide vaccine formula |
| 03/28/2002 | US20020037285 For diseases such as rheumatoid arthritis, atherosclerosis, granulomatous diseases and multiple sclerosis |
| 03/28/2002 | US20020037268 Antimicrobial sanitizing lotion with skin protection properties |
| 03/28/2002 | US20020035998 Method for treatment of cancer and infectious disease |
| 03/28/2002 | US20020035996 Reduction of postoperative complications of cardiopulmonary bypass (CPB) surgery |
| 03/28/2002 | CA2423334A1 Prodrugs of a 7-acylamino-3-heteroarylthio-3-cephem carboxylic acid antibiotic |
| 03/28/2002 | CA2423151A1 Indole derivatives and their use as antifungal and/or antiparasitic agents |
| 03/28/2002 | CA2422923A1 Pyridine derivatives with ikb-kinase (ikk-.beta.) inhibiting activity |
| 03/28/2002 | CA2422911A1 New inhibitors of iapp fibril formation and uses thereof |
| 03/28/2002 | CA2422863A1 Use of immidazoquinolinamines as adjuvants in dna vaccination |
| 03/28/2002 | CA2422576A1 Immunomodulatory preparation |
| 03/28/2002 | CA2422544A1 Conditionally replicating viral vectors and their use |
| 03/28/2002 | CA2422215A1 B7-like molecules and uses thereof |
| 03/28/2002 | CA2421877A1 Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen |
| 03/28/2002 | CA2421485A1 Water soluble rapamycin esters |
| 03/28/2002 | CA2420862A1 Protein phosphatases |
| 03/27/2002 | EP1191036A2 Methods and compositions for diagnosing and treating disorders involving angiogenesis |
| 03/27/2002 | EP1191031A1 3-modified leucomycin derivatives |
| 03/27/2002 | EP1191016A1 Diquaternary ammonium compounds |
| 03/27/2002 | EP1190716A1 The leaves of cajanus cajan(l.) millsp and extract, formulation and uses thereof |
| 03/27/2002 | EP1190715A1 Bactericide against vancomycin resistant enterococcus |
| 03/27/2002 | EP1190257A1 Early detection of flaviviruses using the ns1 glycoprotein |